FIGURE 4 Novel drug modalities for NRF2 activation Up to date, the only NRF2 activators in clinical use are DMF for MS (Rosito et al., 2020), and more recently Omaveloxolone, a semisynthetic terpenoid with potent NRF2-activating effects gained FDA approval in Februrary 2023 for the treatment of Friederichs ataxia ( However, most NRF2 activators are of electrophilic nature and exhibit unpredictable poly-pharmacology
That said, individual targets may vary and should be discussed with your weight management clinician
She shared with me some of her tips that include: 1
From the several sites that can generate superoxide in the mitochondrial matrix, only the superoxide produced at complex III appears to be released both into the matrix and the IMS (Quinlan et al., 2013)
References Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L, et al
In patients with ME/CFS, research has shown that the Krebs cycle is often impaired, with blockages occurring at specific enzymatic steps